Stockscreener 앱 받기
207.82
3.46%
6.845
전일 마감가:
$200.98
열려 있는:
$200.98
하루 거래량:
299.59K
Relative Volume:
0.66
시가총액:
$12.84B
수익:
$534.57M
순이익/손실:
$-293.67M
주가수익비율:
-41.83
EPS:
-4.968
순현금흐름:
$-187.10M
1주 성능:
+0.98%
1개월 성능:
+1.90%
6개월 성능:
+20.85%
1년 성능:
+65.33%
1일 변동 폭
$197.60
$208.32
1주일 범위
$195.03
$208.61
52주 변동 폭
$118.03
$216.45
Ascendis Pharma A S Adr Stock (ASND) Company Profile
ASND을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S Adr
|
208.32 | 12.17B | 534.57M | -293.67M | -187.10M | -4.968 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.33 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.05 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.90 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
830.71 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.73 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-17 | 개시 | Raymond James | Strong Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-06-25 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 개시 | Stifel | Buy |
| 2023-12-20 | 개시 | Jefferies | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Neutral |
| 2023-04-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-04-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-08-30 | 재개 | Berenberg | Buy |
| 2022-03-28 | 재개 | Wedbush | Outperform |
| 2022-03-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 개시 | Cowen | Market Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-30 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 재개 | Stifel | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-10-11 | 개시 | Morgan Stanley | Overweight |
| 2019-03-25 | 개시 | Evercore ISI | Outperform |
| 2019-01-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-01-24 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 개시 | Stifel | Buy |
| 2018-04-02 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-05-11 | 개시 | JP Morgan | Overweight |
| 2017-03-09 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 개시 | Credit Suisse | Outperform |
| 2016-09-26 | 개시 | Wedbush | Outperform |
모두보기
Ascendis Pharma A S Adr 주식(ASND)의 최신 뉴스
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years - Sahm
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ascendis Pharma (NasdaqGS:ASND): Evaluating Valuation as Analyst Confidence Rises on Key EMA Filing - Sahm
Looking Into Ascendis Pharma AS's Recent Short Interest - Sahm
How Ascendis Pharma’s (ASND) TransCon CNP EMA Submission Has Shaped Its Rare Disease Investment Story - Sahm
Should Investors Consider Ascendis Pharma After FDA Nod for Next-Gen Hormone Therapy in 2025? - Sahm
Raymond James initiates Ascendis Pharma stock with Strong Buy rating - Investing.com
Ascendis Pharma A/S Sponsored ADR (ASND) Stock Price Today | Live Chart & News - Traders Union
Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) Target Price at $244.64 - Defense World
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ascendis Pharma’s SWOT analysis: stock soars on Yorvipath success, pipeline potential - Investing.com
Book value per share of Ascendis Pharma A/S Sponsored ADR – MUN:A71 - TradingView
Ascendis Pharma (ASND) Is Up 6.9% After EMA Filing for TransCon CNP in Achondroplasia Treatment - Sahm
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia - Sahm
Does Analyst Backing of Yorvipath Shift the Competitive Narrative for Ascendis Pharma (ASND)? - Sahm
Ascendis Pharma increases share capital following warrant exercises - Investing.com
Earnings call transcript: Ascendis Pharma Q2 2025 beats EPS forecasts - Investing.com
Ascendis Pharma A/S Q2 Earnings Call Highlights Growth - The Globe and Mail
Stocks To Watch: Sociedad Quimica ADR Sees Relative Strength Rating Rise To 80 - inkl
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 92 - Investor's Business Daily
Ascendis Pharma AS earnings beat by €0.45, revenue topped estimates - Investing.com
Ascendis Pharma stock rating reiterated by Cantor Fitzgerald ahead of Q2 results - Investing.com
Ascendis Pharma ADR Shows Rising Price Performance With Jump To 81 RS Rating - Investor's Business Daily
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioNTech SE (BNTX) and Galapagos (GLPG) - The Globe and Mail
Ascendis Pharma stock jumps after FDA approves SKYTROFA for adult GHD - Investing.com
Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 81 RS Rating - MSN
Stocks Showing Rising Market Leadership: Gpo Aeroportuario ADR Earns 83 RS Rating - inkl
Ascendis Pharma reports positive results from hypothyroid trial - MSN
Ascendis Pharma stock rating assumed at Overweight by Morgan Stanley - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize
Canaccord holds Ascendis Pharma stock at $84 target - Investing.com
BofA raises Ascendis Pharma stock target to $216 - Investing.com
Ascendis Pharma ADR Scores Relative Strength Rating Upgrade - MSN
Chagee Holdings ADR Scores Relative Strength Rating Upgrade - inkl
BofA Securities raises Ascendis Pharma stock price target to $201 - Investing.com
European ADRs Climb With Biotech Stocks Leading The Charge - Finimize
Ascendis Pharma stock rises following FDA priority review By Investing.com - Investing.com India
Ascendis Pharma stock rises following FDA priority review - Investing.com
FDA prioritizes review of Ascendis Pharma’s growth disorder drug - Investing.com
Stifel maintains Buy on Ascendis Pharma stock, target at $212 - Investing.com
Ascendis Pharma’s SWOT analysis: strong product pipeline drives stock potential - Investing.com India
Ascendis Pharma grants new employee warrants By Investing.com - Investing.com India
Ascendis Pharma grants new employee warrants - Investing.com
Ascendis Pharma reports growth in achondroplasia trial By Investing.com - Investing.com India
Ascendis Pharma reports growth in achondroplasia trial - Investing.com
Cantor maintains $200 target on Ascendis Pharma stock By Investing.com - Investing.com South Africa
European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize
In the Green: Ascendis Pharma A/S ADR (ASND) Closes at 160.99, Up/Down -1.14 from Previous Day - DWinneX
Ascendis Pharma stock target raised to $245 by JPMorgan - Investing.com
Ascendis Pharma A S Adr (ASND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.29%
0.56%
자본화:
|
볼륨(24시간):